ClinicalTrials.gg
RecruitingNCT05119387GAINUpdated May 19, 2026

Genetic Study of Amyotrophic Lateral Sclerosis in Norway

An observational study in Amyotrophic Lateral Sclerosis, sponsored by Sykehuset Telemark. Recruiting at 17 sites in Norway. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Sykehuset Telemark · Observational

How we know

From the registry’s dates

  • Started Aug 2019; still recruiting 7 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
1,200
Ages
16 Years to 100 Years
Sex
All
01

Study summary

The purpose of this study is to explore the genetic causes relevant for ALS development in Norway.

Read the detailed description

After being informed about the study and potential risks, all patients giving written informed consent will be asked to complete a small questionnaire regarding family history and have a blood sample withdrawn. Blood samples, questionnaires, clinical information and signed consent is send to Department of Medical Genetics, Telemark Hospital Trust were the genetic analysis is performed successively throughout the recruitment period. Patients can choose to have their genetic results returned in a diagnostic setting.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Genetics
  • Amyotrophic Lateral Sclerosis
  • Neurology
  • Clinical genetics
03

In context

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

This study's planned enrollment of 1,200 is above the median of 108 across 266 observational studies indexed under Amyotrophic Lateral Sclerosis.

Browse Amyotrophic Lateral Sclerosis studies →

Lead sponsor

Sykehuset Telemark is the lead sponsor of 33 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals diagnosed with ALS that are being followed through the Norwegian health-care system.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Probable or definite ALS
  • Eligible to consent

Exclusion criteria

Exclusion Criteria:

- not competent to give consent

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
1,200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Individuals diagnosed with ALS

    Individuals diagnosed with ALS that are being followed through the Norwegian health-care system. ALS patients ( probable or definite per El-Escorial criteria)

    Other: Observation

Interventions

  • OtherObservation

    Observation of genetic characteristics

06

What researchers measure

Primary outcomes

  1. Gene frequency

    Number of patients with disease causing mutations in high penetrant ALS genes

    Time frame: 2020-2030

  2. New ALS genes

    Identify new ALS genes in the Norwegian ALS population

    Time frame: 2024-2030

  3. Genetic risk factors

    Identify genetic risk factors for ALS in Norway.

    Time frame: 2022-2030

07

Study locations

17 of 17 sites recruiting
  • Haukeland University Hospital, Department of Neurology
    Bergen, Norway
    Recruiting
    • Ole-Bjørn Tysnes · Contact
  • Nordland Hospital Trust, Department of Neurology
    Bodø, Norway
    Recruiting
    • Karl Bjørnar Alstadhaug · Contact
  • Vestre Viken Hospital Trust, Department of Neurology
    Drammen, Norway
    Recruiting
    • Ingrid Kristine Bjørnå · Contact
  • Førde Hospital Trust, Department of Neurology
    Førde, Norway
    Recruiting
    • Elin Seim · Contact
  • Østfold Hospital Trust, Department of Neurology
    Grålum, Norway
    Recruiting
    • Erika Hallerstig · Contact004769865000
  • Fonna Hospital Trust, Department of Neurology
    Haugesund, Norway
    Recruiting
    • Ineke HogenEsch · Contact
  • Sørlandet Hospital Trust, Department of Neurology
    Kristiansand, Norway
    Recruiting
    • Unn Ljøstad · Contact
  • Innlandet Hospital Trust, Department of Neurology
    Lillehammer, Norway
    Recruiting
    • Grethe Kleveland · Contact
  • Akershus University Hospital, Department of Neurology
    Lørenskog, Norway
    Recruiting
    • Trygve Holmøy · Contact
  • Møre and Romsdal Hospital Trust, Department of Neurology
    Molde, Norway
    Recruiting
    • Åse Hagen Morsund · Contact
  • Nord-Trøndelag Hospital Trust, Department of Neurology
    Namsos, Norway
    Recruiting
    • Anna Grav · Contact
  • Oslo University Hospital, Department of Neurology
    Oslo, Norway
    Recruiting
    • Angelina Maniaol · Contact
  • Telemark Hospital, Department of Neurology
    Skien, Norway
    Recruiting
    • Heidi Flemmen · Contact
  • Stavanger University Hospital, Department of Neurology
    Stavanger, Norway
    Recruiting
    • Katrin Schlüter · Contact
  • University hospital of North Norway, Department of Neurology
    Tromsø, Norway
    Recruiting
    • Agnethe Eltoft · Contact
    • Gudveig Lunde Toverud · Contact
  • St. Olavs Hospital, Department of Neurology
    Trondheim, Norway
    Recruiting
    • Geir Bråthen · Contact
    • Helene Ballo Kvernmo · Sub investigator
  • Vestfold Hospital Trust, Department of Neurology
    Tønsberg, Norway
    Recruiting
    • Natasha Demic · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2019 (actual). Primary completion is estimated for Dec 2030, 136 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2021
First posted
Nov 15, 2021
StartActual
Aug 1, 2019
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05119387
Lead sponsor
Sykehuset Telemark
Collaborators
ALS Norge, Helse Sor-Ost
Responsible party
Sponsor
First posted
Nov 15, 2021
Start date
Aug 1, 2019
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
May 19, 2026

Study contacts

Helle Høyer
Contact
helle.hoyer@sthf.no
35003146 ext. 0047
Helle Høyer
principal investigator · Telemark Hospital Trust, Norway

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion